Investor Presentation Q1 2023
103
Investor presentation
First three months of 2023
International Operations at a glance.
Novo NordiskⓇ
Diabetes trend
Million
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
DKK
billion
19%
17%
First quarter of
2023
Sales
(mDKK)
Growth²
Total GLP-13
8,833
52%
250
100%
600
Long-acting insulin4
2,980
-5%
Premix insulin5
2,637
-7%
200
80%
37.6%¹
GLP-1
Fast-acting insulin
2,737
-11%
400
Human insulin
1,649
-11%
720
150
60%
Insulin
Total insulin
10,003
-8%
587
3.4%1
Other Diabetes care?
487
100
568
-17%
40%
200
Diabetes care
19,404
12%
OAD
50
20%
8.9%1
Obesity care8
1,931
65%
0
0
0%
Diabetes & Obesity
21,335
15%
2021
2030
Population with diabetes
Diabetes growth rate
2045
Feb
2018
Feb
2023
care
Rare disease⁹
2,735
-17%
-GLP-1 MS
-Insulin MS
-OAD MS
Total
24,070
10%
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific; Source: International Diabetes
Federation: Diabetes Atlas 10th Edition 2021
1 CAGR calculated for 5-year period; Competitor insulin value market
shares, as of Feb 2023: Novo Nordisk 51%, Sanofi 27% and Eli Lilly 13%;
Competitor GLP-1 value market shares, as of Feb 2023: Novo Nordisk
65%, Eli Lilly 33% and AstraZeneca 1%; OAD: Oral anti-diabetic; MS:
Market share; Source: IQVIA MAT, Feb 2023 value figures
2 At Constant exchange rates; 3 Comprises Victoza®, Ozempic®, and RybelsusⓇ;
4 Comprises TresibaⓇ, XultophyⓇ and Levemir®: 5 Comprises RyzodegⓇ and
NovoMix®; 6 Comprises FiaspⓇ and NovoRapidⓇ: 7 Comprises Novo NormⓇ and
needles; 8 Obesity care comprises SaxendaⓇ and Wegovy®: 9 Comprises
primarily NovoSeven®, Novo Eight®, NovoThirteen®, Refixia®, EsperoctⓇ,
Norditropin®, Vagifem® and ActivelleⓇView entire presentation